References
1. Creutzig U, Zimmermann M, Reinhardt D, Dworzak M, Stary J, Lehrnbecher T. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. Journal of clinical oncology : official journal of the American Society of Clinical Oncology . Nov 1 2004;22(21):4384-93. doi:10.1200/JCO.2004.01.191
2. Jastaniah W, Abrar MB, Khattab TM. Improved outcome in pediatric AML due to augmented supportive care. Pediatric blood & cancer . Nov 2012;59(5):919-21. doi:10.1002/pbc.24195
3. Woods WG. Curing childhood acute myeloid leukemia (AML) at the half-way point: promises to keep and miles to go before we sleep.Pediatric blood & cancer . May 1 2006;46(5):565-9. doi:10.1002/pbc.20646
4. Flower A, Cairo MS. The evolution of allogeneic stem cell transplant for children and adolescents with acute myeloid leukemia. Clin Adv Hematol Oncol . Jan 2017;15(1):52-62.
5. Santos GW, Tutschka PJ, Brookmeyer R, et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. The New England journal of medicine . Dec 1 1983;309(22):1347-53. doi:10.1056/NEJM198312013092202
6. Nagler A, Rocha V, Labopin M, et al. Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen–a report from the acute leukemia working party of the European group for blood and marrow transplantation. Journal of clinical oncology : official journal of the American Society of Clinical Oncology . Oct 1 2013;31(28):3549-56. doi:10.1200/JCO.2013.48.8114
7. Lee JH, Joo YD, Kim H, et al. Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine. Journal of clinical oncology : official journal of the American Society of Clinical Oncology . Feb 20 2013;31(6):701-9. doi:10.1200/JCO.2011.40.2362
8. Sora F, Grazia CD, Chiusolo P, et al. Allogeneic Hemopoietic Stem Cell Transplants in Patients with Acute Myeloid Leukemia (AML) Prepared with Busulfan and Fludarabine (BUFLU) or Thiotepa, Busulfan, and Fludarabine (TBF): A Retrospective Study. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation . Apr 2020;26(4):698-703. doi:10.1016/j.bbmt.2019.12.725
9. Shimomura Y, Hara M, Yamamoto H, et al. Adding melphalan to fludarabine and a myeloablative dose of busulfan improved survival after allogeneic hematopoietic stem cell transplantation in a propensity score-matched cohort of hematological malignancies. Bone marrow transplantation . Jul 2021;56(7):1691-1699. doi:10.1038/s41409-021-01217-w
10. Lucchini G, Labopin M, Beohou E, et al. Impact of Conditioning Regimen on Outcomes for Children with Acute Myeloid Leukemia Undergoing Transplantation in First Complete Remission. An Analysis on Behalf of the Pediatric Disease Working Party of the European Group for Blood and Marrow Transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation . Mar 2017;23(3):467-474. doi:10.1016/j.bbmt.2016.11.022
11. Katsanis E, Sapp LN, Pelayo-Katsanis L, Whitney K, Zeng Y, Kopp LM. Alternative Donor Hematopoietic Cell Transplantation Conditioned With Myeloablative Busulfan, Fludarabine, and Melphalan is Well Tolerated and Effective Against High-risk Myeloid Malignancies. Journal of pediatric hematology/oncology . Nov 2016;38(8):e315-e318. doi:10.1097/MPH.0000000000000621
12. Katsanis E, Maher K, Roe D, Simpson RJ. Progressive substitution of post-transplant cyclophosphamide with bendamustine: A phase I study in haploidentical bone marrow transplantation. eJHaem May 26, 2020 2020;1(1)(May 26):286-292. doi:10.1002/jha2.20
13. Katsanis E, Stea B, Kovacs K, et al. Feasibility and efficacy of partially replacing post-transplant cyclophosphamide with bendamustine in pediatric and young adult patients undergoing haploidentical bone marrow transplantation. Transplant Cell Ther . Apr 20:S2666-6367(22)01230-1 2022;Apr 20:S2666-6367(22)01230-1; 10.1016/j.jtct.2022.04.015doi:10.1016/j.jtct.2022.04.015
14. Katsanis E, Sapp LN, Varner N, Koza S, Stea B, Zeng Y. Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide/Bendamustine in Pediatric and Young Adult Patients with Hematologic Malignancies. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation . Oct 2018;24(10):2034-2039. doi:10.1016/j.bbmt.2018.06.007
15. Katsanis E, Sapp LN, Reid SC, Reddivalla N, Stea B. T-Cell Replete Myeloablative Haploidentical Bone Marrow Transplantation Is an Effective Option for Pediatric and Young Adult Patients With High-Risk Hematologic Malignancies. Front Pediatr . 2020;8:282. doi:10.3389/fped.2020.00282
16. Jagasia MH, Greinix HT, Arora M, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation . Mar 2015;21(3):389-401 e1. doi:10.1016/j.bbmt.2014.12.001
17. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone marrow transplantation . Jun 1995;15(6):825-8.
18. Clark JR, Scott SD, Jack AL, et al. Monitoring of chimerism following allogeneic haematopoietic stem cell transplantation (HSCT): technical recommendations for the use of short tandem repeat (STR) based techniques, on behalf of the United Kingdom National External Quality Assessment Service for Leucocyte Immunophenotyping Chimerism Working Group. British journal of haematology . Jan 2015;168(1):26-37. doi:10.1111/bjh.13073
19. Kaplan EL, Meier P. Nonparametric Estimation from Incomplete Observations. Journal of the American Statistical Association . 1958/06/01 1958;53(282):457-481. doi:10.1080/01621459.1958.10501452
20. Peto R, Peto J. Asymptotically Efficient Rank Invariant Test Procedures. Journal of the Royal Statistical Society Series A (General) . 1972;135(2):185-207. doi:10.2307/2344317
21. Qayed M, Ahn KW, Kitko CL, et al. A validated pediatric disease risk index for allogeneic hematopoietic cell transplantation. Blood . Feb 18 2021;137(7):983-993. doi:10.1182/blood.2020009342
22. Kanda J, Horwitz ME, Long GD, et al. Outcomes of a 1-day nonmyeloablative salvage regimen for patients with primary graft failure after allogeneic hematopoietic cell transplantation. Bone marrow transplantation . May 2012;47(5):700-5. doi:10.1038/bmt.2011.158
23. Katsanis E, Hennig T, Robinson JE, et al. Revisiting a single day salvage conditioning following graft failure Bone marrow transplantation . 2022;in press
24. Graetz R, Meyer R, Shehab K, Katsanis E. Successful resolution of hyperammonemia following hematopoietic cell transplantation with directed treatment of Ureaplasma parvum infection. Transpl Infect Dis . Apr 2018;20(2):e12839. doi:10.1111/tid.12839
25. Sharma A, Huang S, Li Y, et al. Outcomes of pediatric patients with therapy-related myeloid neoplasms. Bone marrow transplantation . Dec 2021;56(12):2997-3007. doi:10.1038/s41409-021-01448-x
26. Kelly MJ, Horan JT, Alonzo TA, et al. Comparable survival for pediatric acute myeloid leukemia with poor-risk cytogenetics following chemotherapy, matched related donor, or unrelated donor transplantation.Pediatric blood & cancer . Feb 2014;61(2):269-75. doi:10.1002/pbc.24739
27. Majhail NS, Brazauskas R, Hassebroek A, et al. Outcomes of allogeneic hematopoietic cell transplantation for adolescent and young adults compared with children and older adults with acute myeloid leukemia. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation . Jun 2012;18(6):861-73. doi:10.1016/j.bbmt.2011.10.031
28. Spitzer B, Jakubowski AA, Papadopoulos EB, et al. A Chemotherapy-Only Regimen of Busulfan, Melphalan, and Fludarabine, and Rabbit Antithymocyte Globulin Followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplantations for the Treatment of Myeloid Malignancies. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation . Dec 2017;23(12):2088-2095. doi:10.1016/j.bbmt.2017.07.004
29. Edahiro T, Kawase T, Nagoshi H, et al. Allogeneic hematopoietic cell transplantation using fludarabine plus myeloablative busulfan and melphalan confers promising survival in high-risk hematopoietic neoplasms: a single-center retrospective analysis. Hematology . Dec 2021;26(1):186-198. doi:10.1080/16078454.2021.1881228
30. Srinivasan A, Raffa E, Wall DA, et al. Outcome of Haploidentical Peripheral Blood Allografts Using Post-Transplantation Cyclophosphamide Compared to Matched Sibling and Unrelated Donor Bone Marrow Allografts in Pediatric Patients with Hematologic Malignancies: A Single-Center Analysis. Transplant Cell Ther . Mar 2022;28(3):158 e1-158 e9. doi:10.1016/j.jtct.2021.11.009
31. Symons HJ, Zahurak M, Cao Y, et al. Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults. Blood Adv . Aug 25 2020;4(16):3913-3925. doi:10.1182/bloodadvances.2020001648